Scancell Holdings PLC banner

Intrinsic Value

The intrinsic value of Scancell Holdings PLC (SCP) under the Base Case is 0.231 EUR per share. Compared with the current market price of 0.917 EUR, the stock appears Overvalued by 75% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

SCP Intrinsic Value
€0.231
Overvaluation 75%
Intrinsic Value
Price €0.917
Alert me when SCP is below its intrinsic value
Today €0.185 · 79.9% below the current price

SCP is cheaper than usual. Still overvalued, but less so than on 80% of days in the past 5 years.

Alternatives to SCP

Fundamental Analysis

What Scancell Does

Biotechnology Health Care

Scancell Holdings is a UK biotechnology company focused on making new cancer treatments, especially immunotherapies that help the body’s immune system find and attack tumors. Its main work is developing drug candidates in the lab and through clinical trials rather than selling finished medicines today. The company is built around a small number of proprietary platforms, including programs aimed at cancer and some infectious disease targets.

Headquarters
United Kingdom UK
Employees
60
IPO date
Jul 30, 2010
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue SCP Research

Decided on Scancell Holdings? Get an email when SCP reaches the price you’d buy at. Free with an account.

Other Scancell Holdings listings

What is the Intrinsic Value of one SCP stock?

The intrinsic value for Scancell Holdings PLC (SCP) under the Base Case is 0.231 EUR.

Is SCP stock undervalued or overvalued?

Compared with the current market price of 0.917 EUR, the stock appears Overvalued by 75% .

How reliable are our estimates? See how past valuations played out
Back to Top